Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Main phase (the inclusion criteria for the main phase are not reassessed for the extension phase):~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* Male or female, age above or equal to 18 years at the time of signing informed consent. For Korea only: Male or female, age above or equal to 19 years at the time of signing informed consent~* Diagnosed with type 2 diabetes mellitus for at least 90 days prior to day of screening~* HbA1c (glycosylated haemoglobin) 7.5-9.5% (58-80 mmol/mol) (both inclusive)~* Treatment target of HbA1c below 7.0% (53 mmol/mol), as judged by the investigator~* Stable daily dose(s) of 1-2 of the following anti-diabetic drugs within 90 days prior to the day of screening:~* Metformin (equal or above 1500 mg or maximum tolerated dose as documented in the subject medical record)~* Sulfonylureas (equal or above half of the maximum approved dose according to local label or maximum tolerated dose as documented in subject medical record)~* Sodium glucose co-transporter 2 inhibitors~* Thiazolidinediones (equal or above half of the maximum approved dose according to local label or maximum tolerated dose as documented in subject medical record)~Extension phase:~* Informed consent for the extension phase obtained before any trial-related activities for the extension phase.~* On randomised treatment with or without rescue medication at week 52.~Exclusion Criteria:~Main phase (the exclusion criteria for the main phase are not reassessed for the extension phase):~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice). For certain specific countries: Additional specific requirements apply~* Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol~* Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma~* History of pancreatitis (acute or chronic)~* History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery)~* Any of the following: myocardial infarction, stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening and randomisation~* Subjects presently classified as being in New York Heart Association Class IV~* Planned coronary, carotid or peripheral artery revascularisation known on the day of screening~* Subjects with alanine aminotransferase above 2.5 x upper normal limit~* Renal impairment defined as Estimated Glomerular Filtration rate 60 mL/min/1.73 m\^2 as per Chronic Kidney Disease Epidemiology Collaboration formula~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before the day of screening. An exception is short-term insulin treatment for acute illness for a total of below or equal to 14 days~* Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or dilated fundoscopy performed within 90 days prior to randomisation~* History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ)~* History of diabetic ketoacidosis~Extension phase: There are no new exclusion criteria for the extension phase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide flexible dosing (3, 7 or 14 mg) (Type: EXPERIMENTAL): None
- Sitagliptin 100 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete